BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34343635)

  • 1. Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
    Campbell KJ; Leung HY
    Cancer Lett; 2021 Nov; 520():213-221. PubMed ID: 34343635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
    Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
    PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
    Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
    Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.
    Ramesh P; Medema JP
    Apoptosis; 2020 Jun; 25(5-6):305-320. PubMed ID: 32335811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas.
    Müller D; Mazzeo P; Koch R; Bösherz MS; Welter S; von Hammerstein-Equord A; Hinterthaner M; Cordes L; Belharazem D; Marx A; Ströbel P; Küffer S
    BMC Med; 2021 Nov; 19(1):300. PubMed ID: 34781947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X
    Maciel-Silva P; Caldeira I; de Assis Santos I; Carreira ACO; Siqueira FR; Antonioli E; Goldberg AC; Belizário JE; Garay-Malpartida HM
    BMC Cancer; 2018 Jan; 18(1):90. PubMed ID: 29357840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
    Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
    FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
    Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
    Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor.
    Wu X; Zhang LS; Toombs J; Kuo YC; Piazza JT; Tuladhar R; Barrett Q; Fan CW; Zhang X; Walensky LD; Kool M; Cheng SY; Brekken R; Opferman JT; Green DR; Moldoveanu T; Lum L
    Nat Cell Biol; 2017 Oct; 19(10):1226-1236. PubMed ID: 28945232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
    Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
    Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
    Rice SJ; Liu X; Wang HG; Belani CP
    PLoS One; 2019; 14(5):e0217657. PubMed ID: 31150457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.